Retinoblastoma is one of the most common childhood cancer tumours. It can be treated particularly well, provided it is diagnosed in time. However, the visual prognosis can be compromised depending on the location of the tumour and the impact of treatment on the retina.


Supported project 

In 2018-2019, L'OCCITANE Manosque and the Foundation supported the Institut Curie in its project to fight retinoblastoma. This project aimed to optimize the treatment of retinoblastoma by PDT (photodynamic therapy) in mouse models of the human disease with the aim of applying for rare drug status and performing clinical trials for pediatric use.

Some figures

Budget 10,000 euros